MergerLinks Header Logo

Submit Deal

Submit Deal

Announced

Completed

Viatris completed the acquisition of a 5.1% stake in Syngene from Biocon for $153m.

Synopsis

Viatris, a global pharmaceutical company, completed the acquisition of a 5.1% stake in Syngene, an innovation-led contract research, development and manufacturing organization, from Biocon, an Indian biopharmaceutical company, for $153m.

Principals

SYNGENE

target

SYNGENE

VIATRIS

bidder

VIATRIS

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Dealmakers (8)

Service Providers

Sort

Jonathan Hunt

Jonathan Hunt

ManagerCEO at SYNGENE
Deal Bio
Total Deals
2/
Total Value
£137M
Sibaji Biswas

Sibaji Biswas

ManagerCFO at SYNGENE
Deal Bio
Total Deals
2/
Total Value
£137M
Indranil Sen

Indranil Sen

ManagerCFO at BIOCON BIOLOGICS LTD
Deal Bio
Total Deals
1/
Total Value
£137M
Siddharth Mittal

Siddharth Mittal

ManagerCEO at BIOCON BIOLOGICS LTD
Deal Bio
Total Deals
1/
Total Value
£137M
Chintan Kothari

Chintan Kothari

Financial AdvisorExecutive Director at Avendus
Deal Bio
Total Deals
4/
Total Value
£427M
Gaurav Sood

Gaurav Sood

Financial AdvisorManaging Director & Head, Equity Capital Markets at Avendus
Deal Bio
Total Deals
4/
Total Value
£495M
Sanjeev Narula

Sanjeev Narula

ManagerCFO at VIATRIS
Deal Bio
Total Deals
6/
Total Value
£5,269M
Michael Goettler

Michael Goettler

ManagerCEO at VIATRIS
Deal Bio
Total Deals
3/
Total Value
£18,903M

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US